Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mikhail Scherbak"'
Autor:
Aleksandras Laucevičius, Gabrielius Jakutis, Gitana Zuoziene, Mikhail Scherbak, Jelena Celutkiene, Birute Petrauskiene, Ekaterina Trush, Greta Burneikaite, Yury Vasyuk, Evgeny Shkolnik
Publikováno v:
Coronary Artery Disease. 29:579-586
Despite major advances in managing coronary artery disease and continuous research on alternative techniques to enhance myocardial perfusion and reduce symptoms, coronary artery disease is still one of the leading causes of adult disability worldwide
Autor:
Aleksandras Laucevičius, Evgeny Shkolnik, Yury Vasyuk, Greta Burneikaite, Birute Petrauskiene, Gitana Zuoziene, Ekaterina Trush, Mikhail Scherbak, Jelena Celutkiene
Publikováno v:
Anatolian Journal of Cardiology
Objective Despite revascularization and optimal medical treatment (OMT), patients with angina often have a reduced quality of life due to inadequate relief from symptoms. Recent studies have shown that the application of shock waves may reduce angina
Autor:
Gitana Zuoziene, Yury Vasyuk, Jelena Celutkiene, Greta Burneikaite, Evgeny Shkolnik, Irena Butkuviene, Ekaterina Trush, Birute Petrauskiene, Aleksandras Laucevičius, Mikhail Scherbak
Publikováno v:
Journal of the American College of Cardiology. 71:A216
recent studies showed that the application of low intensity shockwaves may induce angiogenesis and ameliorate myocardial ischemia in patients with refractory angina. The aim of the study was to investigate the efficacy of cardiac shock wave therapy (
Autor:
Alen Marijam, Ekaterina Safonova, Mikhail Scherbakov, Evgeniy Shpeer, Desirée Van Oorschot, Alla Rudakova, Vladimir Tatochenko, Nikolay Briko
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 5 (2022)
This economic evaluation assesses the cost-effectiveness and budget impact of introducing a two-dose varicella vaccine in the Russian national immunization program. A static Markov model followed a simulated 2019 Russian cohort over its lifetime and
Externí odkaz:
https://doaj.org/article/b02b4a1b3b8a4ec18acb2fb8dc9b5fff